Not provided
Not provided
Not provided
Not provided
Not provided
Data on initial patients sufficient
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects
This study performs the first clinical evaluation of the Gen1B (OA-16-1S) duplex OA/US probe. This probe includes design changes to improve reliability and performance compared to the Gen1 (OA-16-1) duplex OA/US probe. The performance of the Gen1 duplex probe is functionally equivalent to the PIONEER duplex probe (OA-15-3), which was used in previous clinical studies for suspicious breast masses.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Imagio Gen 1B | Active Comparator | Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe |
|
| Imagio Gen 1 | Active Comparator | Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gen 1B | Device | Diagnostic Ultrasound and Optoacoustic Imaging |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects with Treatment-related Events | Safety of the Gen 1B duplex Optoacoustic (OA)/ Ultrasound (US) probe in breast applications as compared to Gen 1 with respect to treatment-related events | At end of study, average of six months |
| Diagnostic Image Quality of Gen 1B | Independent reader comparison using questionnaire and measurements on artifacts and features of Gen 1 Gen1B probe images for pair wise comparison | At end of study, average of six months |
| Measure | Description | Time Frame |
|---|---|---|
| Probe performance data comparison across skin types | The effect of skin pigmentation using the Fitzpatrick Scale (skin typing test), from Type I (always burns, never tans (palest; freckles) to Type VI never burns (deeply pigmented dark brown to darkest brown) will be used to determine similarities and differences between probes. | At end of study, average of six months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| A. Thomas Stavros, MD | Seno Medical | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seno Medical | San Antonio | Texas | 78230 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Unblinded feasibility study in healthy subjects
Not provided
Not provided
Not provided
Not provided
| Gen 1 | Device | Diagnostic Ultrasound and Optoacoustic Imaging |
|
| Image Quality between probes at reduced laser level | OA images with reduced laser level energy will be collected to determine via a 7 point image quality scale, where 1 is poor and 7 is best, which probe produces better images by independent readers | At end of study, average of six months |
| D017437 |
| Skin and Connective Tissue Diseases |